Concomitant ALK translocation and EGFR mutation in lung cancer: A comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 348-354

  Won, J K ^a   Keam, B ^a   Koh, J ^a   Cho, H J ^a   Jeon, Yoon Kyung ^a   Kim, T M ^a   Lee, S H ^a   Lee, D S ^a   Kim, D W ^a   Chung, D H ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

ALK; EGFR; Lung cancer; Next generation sequencing; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONE;

ADOLESCENT; ADULT; AGED; ALK GENE; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIRECT SEQUENCING; DRUG RESPONSE; DRUG TREATMENT FAILURE; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTANT ENRICHED NEXT GENERATION SEQUENCING ASSAY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PEPTIDE NUCLEIC ACID CLAMPING REAL TIME POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SMALL CELL CARCINOMA; TREATMENT DURATION; TUMOR BIOPSY; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MUTATION; PROCEDURES; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY; SULFONES; TRANSLOCATION, GENETIC;

EID: 84925299472     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu530     Document Type: Article

References (26)

1. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137: 828-860.
2. Goto K, Satouchi M, Ishii G et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012; 23: 2914-2919.
3. Kim HJ, Lee KY, Kim YC et al. Detection and comparison of peptide nucleic acidmediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with nonsmall cell lung cancer. Lung Cancer 2012; 75: 321-325.
4. de Biase D, Visani M, Malapelle U et al. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS One 2013; 8: e83607.
5. Kim HS, Sung JS, Yang SJ et al. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma. PLoS One 2013; 8: e81975.
6. Gainor JF, Varghese AM, Ou SH et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19: 4273-4281.
7. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16: 5581-5590.
8. Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010; 9: 188.
9. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-6060.
10. Boland JM, Jang JS, Li J et al. MET and EGFR mutations identified in ALKrearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 2013; 8: 574-581.
11. Lee JK, Kim TM, Koh Y et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012; 77: 460-463.
12. Cabillic F, Gros A, Dugay F et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014; 9: 295-306.
13. Santelmo C, Ravaioli A, Barzotti E et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung Cancer 2013; 81: 294-296.
14. Chen X, Zhang J, Hu Q et al. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer 2013; 81: 308-310.
15. Miyanaga A, Shimizu K, Noro R et al. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer 2013; 13: 262.
16. Yang JJ, Zhang XC, Su J et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014; 20: 1383-1392.
17. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-1482.
18. Bai H, Wang Z, Wang Y et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One 2013; 8: e54170.
19. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
20. Gottschling S, Herpel E, Eberhardt WE et al. The gefitinib long-term responder (LTR)-a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP). Lung Cancer 2012; 77: 183-191.
21. van der Wekken AJ, Stigt JA, A'T Hart N. A novel EGFR mutation in exon 19 showed stable disease after TKI treatment. J Thorac Oncol 2012; 7: e8.
22. Lee JK, Shin JY, Kim S et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol 2013; 24: 2080-2087.
23. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 3316-3321.
24. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
25. Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics 2006; 172: 2557-2566.
26. Kim S, Kim TM, Kim DW et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013; 8: 415-422.